Article Sidebar
Main Article Content
Abstract
Background: Chronic constipation (CC) refractory to conventional laxatives is a prevalent clinical challenge that significantly impairs quality of life. Ileal bile acid transporter (IBAT) inhibitors, a novel class of drugs, modulate colonic function by increasing the delivery of bile acids to the colon. This study aimed to quantitatively synthesize the evidence for the efficacy and safety of IBAT inhibitors in this difficult-to-treat population to clarify their position in the therapeutic algorithm.
Methods: Following PRISMA guidelines, we systematically searched PubMed, Scopus, Embase, and Cochrane CENTRAL, along with clinical trial registries, from inception to June 1st, 2025. We included parallel-group, randomized controlled trials (RCTs) comparing the IBAT inhibitor elobixibat with placebo in adults with CC refractory to at least two prior laxative classes. The primary efficacy outcome was the overall responder rate. Key secondary outcomes included change in spontaneous bowel movements (SBMs) per week, quality of life (QoL) scores, and incidence of adverse events. Data were pooled using a random-effects model. Number needed to treat (NNT) and to harm (NNH) were calculated.
Results: Our search identified six eligible RCTs enrolling 2,155 patients. Patients treated with elobixibat were significantly more likely to be responders compared to placebo (Risk Ratio [RR] = 2.58; 95% CI: 1.87–3.56; p < 0.00001), with moderate heterogeneity (I² = 59%). The NNT to achieve one additional responder was 5 (95% CI: 4–7). Elobixibat significantly increased the mean number of SBMs per week (Mean Difference [MD] = 1.65; 95% CI: 1.19–2.11; p < 0.00001; I² = 64%). The most common adverse events were gastrointestinal; elobixibat significantly increased the risk of diarrhea (RR = 4.21; 95% CI: 3.01–5.89; NNH = 6) and abdominal pain (RR = 2.35; 95% CI: 1.63–3.38; NNH = 11). Most events were mild to moderate.
Conclusion: This meta-analysis provides robust evidence that the IBAT inhibitor elobixibat is a highly effective therapy for refractory CC, offering a significant improvement in symptoms for a substantial portion of patients. This benefit must be carefully balanced against the high incidence of mechanism-based gastrointestinal side effects. These findings establish elobixibat as a potent, mechanistically distinct option, thereby informing its strategic placement on the therapeutic ladder for patients failed by conventional laxatives.
Keywords
Article Details
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
